Research programme: polyclonal antibody therapies - ExcelimmuneAlternative Names: Staphguard
Latest Information Update: 21 Dec 2011
At a glance
- Originator Excelimmune
- Class Polyclonal antibodies
- Mechanism of Action Immunomodulators
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Preclinical Methicillin-resistant Staphylococcus aureus infections
Most Recent Events
- 21 Dec 2011 Preclinical development is ongoing in USA